ChromoGenics AB

As of June 30, 2024, ChromoGenics AB has 6.63M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 5.36, and the price-to-book ratio stands at -0.07.

These figures are as of June 30, 2024. The EV/Sales ratio of 7.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2024, ChromoGenics AB maintains a current ratio of 0.68, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.78, indicating elevated leverage, while an interest coverage ratio of -2.50 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -13.68, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 1.74, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.04 indicates how many times ChromoGenics AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 30, 2024, ChromoGenics AB's stock has gained approximately 54.75% over the past 52 weeks. The 50-day moving average sits at 9.87, while the 200-day moving average is 8.34.

Over the twelve months ended June 30, 2024, ChromoGenics AB posted a gross margin of -33.03, reflecting its pricing power and cost economics. The operating margin of -161.01 and net profit margin of -221.29 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -92.74: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -86.88, meaning ChromoGenics AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ChromoGenics AB's most recent stock split took place on September 11, 2023 with a 100:1 split ratio.

As of June 30, 2024, ChromoGenics AB has an Altman Z-Score of -8.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.